REVIEW ARTICLE
Membranous glomerulonephritis – a common, unspecific pattern of glomerular injury
Submission date: 2018-05-06
Final revision date: 2018-06-26
Acceptance date: 2018-08-02
Publication date: 2018-11-20
Pol J Pathol 2018;69(3):209-218
KEYWORDS
TOPICS
ABSTRACT
Membranous nephropathy (MN) is a chronic form of glomerulonephritis, associated with the presence of immune complexes beneath the podocytes on the subepithelial region of glomerular capillaries. MN is not a disease entity but one of relatively common patterns of glomerular injury that may be a manifestation of primary renal autoimmunological reaction or may evolve as a phenomenon secondary to wide spectrum of systemic processes.
REFERENCES (103)
1.
Perkowska-Ptasinska A, Bartczak A, Wagrowska-Danilewicz M, et al. Clinicopathologic correlations of renal pathology in the adult population of Poland. Nephrol Dial Transplant 2017; 32 (suppl 2): ii209-ii218.
2.
Hanko JB, Mullan RN, O’Rourke DM, et al. The changing pattern of adult primary glomerular disease. Nephrol Dial Transplant 2009; 24: 3050-3054.
3.
Maixnerova D, Jancova E, Skibova J, et al. Nationwide biopsy survey of renal diseases in the Czech Republic during the years 1994-2011. J Nephrol 2015; 28: 39-49.
4.
Perkowska-Ptasinska A, Deborska-Materkowska D, Bartczak A, et al. Kidney disease in the elderly: biopsy based data from 14 renal centers in Poland. BMC Nephrol 2016; 17: 194.
5.
Nationwide and Long-Term Survey of Primary Glomerulonephritis in Japan as Observed in 1,850 Biopsied Cases. Nephron 1999; 82: 205-213.
6.
Sim JJ, Batech M, Hever A, et al. Distribution of Biopsy-Proven Presumed Primary Glomerulonephropathies in 2000-2011 Among a Racially and Ethnically Diverse US Population. Am J Kidney Dis 2016; 68: 533-544.
7.
Choi IJ, Jeong HJ, Han DS, et al. An analysis of 4,514 cases of renal biopsy in Korea. Yonsei Med J 2001; 42: 247-254.
8.
McGrogan A, Franssen CF, de Vries CS. The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. Nephrol Dial Transplant 2011; 26: 414-430.
10.
Mellors RC, Ortega LG, Holman HR. Role of gamma globulins in pathogenesis of renal lesions in systemic lupus erythematosus and chronic membranous glomerulonephritis, with an observation on the lupus erythematosus cell reaction. J Exp Med 1957; 106: 191-202.
11.
Farquhar MG, Saito A, Kerjaschki D, et al. The Heymann nephritis antigenic complex: megalin (gp330) and RAP. J Am Soc Nephrol 1995; 6: 35-47.
12.
Border WA, Ward HJ, Kamil ES, et al. Induction of membranous nephropathy in rabbits by administration of an exogenous cationic antigen. J Clin Invest 1982; 69: 451-461.
13.
Koyama A, Inage H, Kobayashi M, et al. Effect of chemical cationization of antigen on glomerular localization of immune complexes in active models of serum sickness nephritis in rabbits. Immunology 1986; 58: 529-534.
14.
Debiec H, Lefeu F, Kemper MJ, et al. Early-childhood membranous nephropathy due to cationic bovine serum albumin. N Engl J Med 2011; 364: 2101-2110.
15.
Debiec H, Guigonis V, Mougenot B, et al. Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies. N Engl J Med 2002; 346: 2053-2060.
16.
Debiec H, Guigonis V, Mougenot B, et al. Antenatal membranous glomerulonephritis with vascular injury induced by anti-neutral endopeptidase antibodies: toward new concepts in the pathogenesis of glomerular diseases. J Am Soc Nephrol 2003; 14 Suppl 1: S27-S32.
17.
Debiec H, Nauta J, Coulet F, et al. Role of truncating mutations in MME gene in fetomaternal alloimmunisation and antenatal glomerulopathies. Lancet 2004; 364: 1252-1259.
18.
Vivarelli M, Emma F, Pellé T, et al. Genetic homogeneity but IgG subclass-dependent clinical variability of alloimmune membranous nephropathy with anti-neutral endopeptidase antibodies. Kidney Int 2015; 87: 602-609.
19.
Beck LH Jr, Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009; 361: 11-21.
20.
Beck LH Jr, Fervenza FC, Beck DM, et al. Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol 2011; 22: 1543-1550.
21.
Timmermans SA, Abdul Hamid MA, Cohen Tervaert JW, et al. Anti-PLA2R Antibodies as a Prognostic Factor in PLA2R-Related Membranous Nephropathy. Am J Nephrol 2015; 42: 70-77.
22.
Svobodova B, Honsova E, Ronco P, et al. Kidney biopsy is a sensitive tool for retrospective diagnosis of PLA2R-related membranous nephropathy. Nephrol Dial Transplant 2013; 28: 1839-1844.
23.
Hara S, Goto S, Kamiura N, et al. Reappraisal of PLA2R1 in membranous nephropathy: immunostaining method influence and association with IgG4-dominant phenotype. Virchows Arch 2015; 467: 87-94.
24.
Cattran DC, Brenchley PE. Membranous nephropathy: integrating basic science into improved clinical management. Kidney Int 2017; 91: 566-574.
25.
Dai H, Zhang H, He Y. Diagnostic accuracy of PLA2R autoantibodies and glomerular staining for the differentiation of idiopathic and secondary membranous nephropathy: an updated meta-analysis. Sci Rep 2015; 5: 8803.
26.
Du Y, Li J, He F, et al. The diagnosis accuracy of PLA2R-AB in the diagnosis of idiopathic membranous nephropathy: a meta-analysis. PLoS One 2014; 9: e104936.
27.
Stehlé T, Audard V, Ronco P, et al. Phospholipase A2 receptor and sarcoidosis-associated membranous nephropathy. Nephrol Dial Transplant 2015; 30: 1047-1050.
28.
Xie Q, Li Y, Xue J, et al. Renal phospholipase A2 receptor in hepatitis B virus-associated membranous nephropathy. Am J Nephrol 2015; 41: 345-353.
29.
Tomas NM, Beck LH Jr, Meyer-Schwesinger C, et al. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med 2014; 371: 2277-2287.
30.
Larsen CP, Cossey LN, Beck LH. THSD7A staining of membranous glomerulopathy in clinical practice reveals cases with dual autoantibody positivity. Mod Pathol 2016; 29: 421-426.
31.
Iwakura T, Ohashi N, Kato A, et al. Prevalence of Enhanced Granular Expression of Thrombospondin Type-1 Domain-Containing 7A in the Glomeruli of Japanese Patients with Idiopathic Membranous Nephropathy. PLoS One 2015; 10: e0138841.
32.
Tomas NM, Hoxha E, Reinicke AT, et al. Autoantibodies against thrombospondin type 1 domain-containing 7A induce membranous nephropathy. J Clin Invest 2016; 126: 2519-2532.
33.
Abe S, Amagasaki Y, Konishi K, et al. Idiopathic membranous glomerulonephritis: aspects of geographical differences. J Clin Pathol 1986; 39: 1193-1198.
34.
Donadio JV Jr, Burgess JH, Holley KE. Membranous lupus nephropathy: a clinicopathologic study. Medicine (Baltimore) 1977; 56: 527-536.
35.
Nawaz FA, Larsen CP, Troxell ML. Membranous nephropathy and nonsteroidal anti-inflammatory agents. Am J Kidney Dis 2013; 62: 1012-1017.
36.
Makino H, Yoshinaga Y, Yamasaki Y, et al. Renal involvement in rheumatoid arthritis: analysis of renal biopsy specimens from 100 patients. Mod Rheumatol 2002; 12: 148-154.
37.
Hall CL, Jawad S, Harrison PR, et al. Natural course of penicillamine nephropathy: a long term study of 33 patients. Br Med J (Clin Res Ed) 1988; 296: 1083-1086.
38.
Lai KN, Li PK, Lui SF et al. Membranous nephropathy related to hepatitis B virus in adults. N Engl J Med 1991; 324: 1457-1463.
39.
Ozkok A, Yildiz A. Hepatitis C virus associated glomerulopathies. World J Gastroenterol 2014; 20: 7544-7554.
40.
Araújo Sde A, Giordano LF, Rosa AA, et al. Membranous glomerulonephritis secondary to syphilis. Braz J Infect Dis 2015; 19: 442-443.
41.
Hiramatsu R, Ubara Y, Sawa N, et al. Clinicopathological analysis of allogeneic hematopoietic stem cell transplantation-related membranous glomerulonephritis. Hum Pathol 2016; 50: 187-194.
42.
Lefaucheur C, Stengel B, Nochy D, et al. Membranous nephropathy and cancer: Epidemiologic evidence and determinants of high-risk cancer association. Kidney Int 2006; 70: 1510-1517.
43.
Leeaphorn N, Kue-A-Pai P, Thamcharoen N, et al. Prevalence of cancer in membranous nephropathy: a systematic review and meta-analysis of observational studies. Am J Nephrol 2014; 40: 29-35.
44.
Lee JC, Yamauchi H, Hopper J Jr. The association of cancer and the nephrotic syndrome. Ann Intern Med 1966; 64: 41-51.
45.
Qu Z, Liu G, Li J, et al. Absence of glomerular IgG4 deposition in patients with membranous nephropathy may indicate malignancy. Nephrol Dial Transplant 2012; 27: 1931-1937.
46.
Lönnbro-Widgren J, Ebefors K, Mölne J, et al. Glomerular IgG subclasses in idiopathic and malignancy-associated membranous nephropathy. Clin Kidney J 2015; 8: 433-439.
47.
Alnasrallah B, Collins JF, Zwi LJ. Malignancy in membranous nephropathy: evaluation of incidence. Int J Nephrol 2017; 2017: 8409829.
48.
Murtas C, Ghiggeri GM. Membranous glomerulonephritis: histological and serological features to differentiate cancer-related and non-related forms. J Nephrol 2016; 29: 469-478.
49.
Pani A, Porta C, Cosmai L, et al. Glomerular diseases and cancer: evaluation of underlying malignancy. J Nephrol 2016; 29: 143-152.
50.
Larsen CP, Ambuzs JM, Bonsib SM, et al. Membranous-like glomerulopathy with masked IgG kappa deposits. Kidney Int 2014; 86: 154-161.
51.
Bantis C, Heering PJ, Aker S, et al. Tumor necrosis factor-alpha gene G-308A polymorphism is a risk factor for the development of membranous glomerulonephritis. Am J Nephrol 2006; 26: 12-15.
52.
Chen SY, Chen CH, Huang YC, et al. Association of STAT4 polymorphisms with susceptibility to primary membranous glomerulonephritis and renal failure. Clin Chim Acta 2011; 412: 1899-904.
53.
Stanescu HC, Arcos-Burgos M, Medlar A, et al. Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy. N Engl J Med 2011; 364: 616-626.
54.
Lv J, Hou W, Zhou X, et al. Interaction between PLA2R1 and HLA-DQA1 variants associates with anti-PLA2R antibodies and membranous nephropathy. J Am Soc Nephrol 2013; 24: 1323-1329.
55.
Ramachandran R, Kumar V, Kumar A, et al. PLA2R antibodies, glomerular PLA2R deposits and variations in PLA2R1 and HLA-DQA1 genes in primary membranous nephropathy in South Asians. Nephrol Dial Transplant 2016; 31: 1486-1493.
56.
Churg J, Ehrenreich T. Membranous nephropathy. Perspect Nephrol Hypertens 1973; 1 Pt 1: 443-448.
57.
Paraskevakou H, Kavantzas N, Pavlopoulos PM, et al. Membranous glomerulonephritis: a morphometric study. Pathol Res Pract 2000; 196: 141-144.
58.
Ruggenenti P, Cravedi P, Sghirlanzoni MC, et al. Effects of rituximab on morphofunctional abnormalities of membranous glomerulopathy. Clin J Am Soc Nephrol 2008; 3: 1652-1659.
59.
Morita M, Mii A, Shimizu A, et al. Glomerular endothelial cell injury and focal segmental glomerulosclerosis lesion in idiopathic membranous nephropathy. PLoS One 2015; 10: e0116700.
60.
Gu QH, Cui Z, Huang J, et al. Patients With Combined Membranous Nephropathy and Focal Segmental Glomerulosclerosis Have Comparable Clinical and Autoantibody Profiles With Primary Membranous Nephropathy: A Retrospective Observational Study. Medicine (Baltimore) 2016; 95: e3786.
61.
Mariani LH, Martini S, Barisoni L, et al. Interstitial fibrosis scored on whole-slide digital imaging of kidney biopsies is a predictor of outcome in proteinuric glomerulopathies. Nephrol Dial Transplant 2018; 33: 310-318.
62.
Tsuboi N, Kawamura T, Miyazaki Y, et al. Low glomerular density is a risk factor for progression in idiopathic membranous nephropathy. Nephrol Dial Transplant 2011; 26: 3555-3560.
63.
Sprangers B, Bomback AS, Cohen SD, et al. Idiopathic membranous nephropathy: clinical and histologic prognostic features and treatment patterns over time at a tertiary referral center. Am J Nephrol 2012; 36: 78-89.
64.
Yokoyama H, Taguchi T, Sugiyama H, et al. Membranous nephropathy in Japan: analysis of the Japan Renal Biopsy Registry (J-RBR). Clin Exp Nephrol 2012; 16: 557-63.
65.
Hogan SL, Muller KE, Jennette JC, et al. A review of therapeutic studies of idiopathic membranous glomerulopathy. Am J Kidney Dis 1995; 25: 862-875.
66.
Cattran DC, Pei Y, Greenwood CM, et al. Validation of a predictive model of idiopathic membranous nephropathy: its clinical and research implications. Kidney Int 1997; 51: 901-907.
67.
Hoxha E, Thiele I, Zahner G, et al. Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy. J Am Soc Nephrol 2014; 25: 1357-1366.
68.
Segawa Y, Hisano S, Matsushita M, et al. IgG subclasses and complement pathway in segmental and global membranous nephropathy. Pediatr Nephrol 2010; 25: 1091-1099.
69.
Kuroki A, Shibata T, Honda H, et al. Glomerular and serum IgG subclasses in diffuse proliferative lupus nephritis, membranous lupus nephritis, and idiopathic membranous nephropathy. Intern Med 2002; 41: 936-942.
70.
Kearney N, Podolak J, Matsumura L, et al. Patterns of IgG subclass deposits in membranous glomerulonephritis in renal allografts. Transplant Proc 2011; 43: 3743-3746.
71.
Ohtani H, Wakui H, Komatsuda A, et al. Distribution of glomerular IgG subclass deposits in malignancy-associated membranous nephropathy. Nephrol Dial Transplant 2004; 19: 574-579.
72.
Ma LJ, Fogo AB. PAI-1 and kidney fibrosis. Front Biosci (Landmark Ed) 2009; 14: 2028-2041.
73.
Scharpé J, Maes B, Van Damme B. The podocyte: from bench to bedside. Acta Clin Belg 2005; 60: 86-93.
74.
Müller-Deile J, Dannenberg J, Schroder P, et al. Podocytes regulate the glomerular basement membrane protein nephronectin by means of miR-378a-3p in glomerular diseases. Kidney Int 2017; 92: 836-849.
75.
Saran AM, Yuan H, Takeuchi E, et al. Complement mediates nephrin redistribution and actin dissociation in experimental membranous nephropathy. Kidney Int 2003; 64: 2072-2078.
76.
Cunningham PN, Quigg RJ. Contrasting roles of complement activation and its regulation in membranous nephropathy. J Am Soc Nephrol 2005; 16: 1214-1222.
77.
Nangaku M, Shankland SJ, Couser WG. Cellular response to injury in membranous nephropathy. J Am Soc Nephrol 2005; 16: 1195-1204.
78.
Nosaka H, Tamura Y, Kojima K, et al. Podocyte foot process effacement in very early phase of passive Heymann nephritis is not a prerequisite for proteinuria. J Nephrol 2009; 22: 484-490.
79.
Yang Y, Wang C, Jin L, et al. IgG4 anti-phospholipase A2 receptor might activate lectin and alternative complement pathway meanwhile in idiopathic membranous nephropathy: an inspiration from a cross-sectional study. Immunol Res 2016; 64: 919-930.
80.
Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol 2014; 5: 520.
81.
Lhotta K, Würzner R, König P. Glomerular deposition of mannose-binding lectin in human glomerulonephritis. Nephrol Dial Transplant 1999; 14: 881-886.
82.
Bally S, Debiec H, Ponard D, et al. Phospholipase A2 Receptor-Related Membranous Nephropathy and Mannan-Binding Lectin Deficiency. J Am Soc Nephrol 2016; 27: 3539-3544.
83.
Tegla CA, Cudrici C, Patel S, et al. Membrane attack by complement: the assembly and biology of terminal complement complexes. Immunol Res 2011; 51: 45-60.
84.
Bohana-Kashtan O, Ziporen L, Donin N, et al. Cell signals transduced by complement. Mol Immunol 2004; 41: 583-597.
85.
Spicer ST, Tran GT, Killingsworth MC, et al. Induction of passive Heymann nephritis in complement component 6-deficient PVG rats. J Immunol 2007; 179: 172-178.
86.
Leenaerts PL, Hall BM, Van Damme BJ, et al. Active Heymann nephritis in complement component C6 deficient rats. Kidney Int 1995; 47: 1604-1614.
87.
Reiser J, von Gersdorff G, Loos M, et al. Induction of B7-1 in podocytes is associated with nephrotic syndrome. J Clin Invest 2004; 113: 1390-1397.
88.
Polanco N, Gutiérrez E, Covarsí A, et al. Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol 2010; 21: 697-704.
89.
van den Brand JA, van Dijk PR, Hofstra JM, et al. Long-term outcomes in idiopathic membranous nephropathy using a restrictive treatment strategy. J Am Soc Nephrol 2014; 25: 150-158.
90.
Ponticelli C. Prognosis and treatment of membranous nephropathy. Kidney Int 1986; 29: 927-940.
91.
van de Logt AE, Hofstra JM, Wetzels JF. Pharmacological treatment of primary membranous nephropathy in 2016. Expert Rev Clin Pharmacol 2016; 9: 1463-1478.
92.
Cattran D, Brenchley P. Membranous nephropathy: thinking through the therapeutic options. Nephrol Dial Transplant 2017; 32 (suppl. 1): i22-i29.
93.
Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for Glomerulonephritis 2012.
94.
Alfaadhel T, Cattran D. Management of Membranous Nephropathy in Western Countries. Kidney Dis (Basel) 2015; 1: 126-137.
95.
Barbour SJ, Greenwald A, Djurdjev O, et al. Disease-specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis. Kidney Int 2012; 81: 190-195.
96.
du Buf-Vereijken PW, Wetzels JF. Efficacy of a second course of immunosuppressive therapy in patients with membranous nephropathy and persistent or relapsing disease activity. Nephrol Dial Transplant 2004; 19: 2036-2043.
97.
Golgert WA, Appel GB, Hariharan S. Recurrent glomerulonephritis after renal transplantation: an unsolved problem. Clin J Am Soc Nephrol 2008; 3: 800-807.
98.
Mirza MK, Kim L, Kadambi PV, et al. Membranous nephropathy transplanted in the donor kidney: observations of resolving glomerulopathy in serial allograft biopsies. Nephrol Dial Transplant 2014; 29: 2343-2347.
99.
Aline-Fardin A, Rifle G, Martin L, et al. Recurent and de novo membranous glomerulopathy after kidney transplantation. Transplant Proc 2009; 41: 669-671.
100.
Pippias M, Stel VS, Aresté-Fosalba N, et al. Long-term Kidney Transplant Outcomes in Primary Glomerulonephritis: Analysis From the ERA-EDTA Registry. Transplantation 2016; 100: 1955-1962.
101.
Cosio FG, Cattran DC. Recent advances in our understanding of recurrent primary glomerulonephritis after kidney transplantation. Kidney Int 2017; 91: 304-314.
102.
Ponticelli C, Glassock RJ. De novo membranous nephropathy (MN) in kidney allografts. A peculiar form of alloimmune disease? Transpl Int 2012; 25: 1205-10.
103.
Wen J, Xie K, Zhang M et al. HLA-DR, and not PLA2R, is expressed on the podocytes in kidney allografts in de novo membranous nephropathy. Medicine (Baltimore) 2016; 95: e4809.
| eISSN: | 2084-9869 |
| ISSN: | 1233-9687 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
